The regulator NICE says the drug, called pembrolizumab, will be offered to patients with advanced forms of endometrial cancer.
The Royal Marsden in Sutton is set to be among the first to offer this treatment, building on their leading roles in cancer care and trials.
It’ll be available immediately through the Cancer Drugs Fund, which covers the cost of certain treatments in England.
